Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
Global Climate Change01:50

Global Climate Change

29.1K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
29.1K
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

612
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
612
Errors in Global Positioning System01:26

Errors in Global Positioning System

364
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
364
Global Regulatory Systems01:28

Global Regulatory Systems

735
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
735
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

333
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing the Eat, Sleep, Console (ESC) Model in a Small Safety-Net Hospital: A Phased Quality Improvement Initiative.

Cureus·2026
Same author

Antenatal Corticosteroid Exposure in Late Preterm Infants: Clinical Considerations in Diabetic Mothers.

Cureus·2026
Same author

Polyunsaturated Fatty Acid Balance Modulates Microglial State in a Murine Model of Oxygen-Induced Neovascularization.

Nutrients·2026
Same author

Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery and Community Participation Following Stroke. Part One: Stroke Rehabilitation Planning for Optimal Care Delivery, 7th Edition Update 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Canadian Stroke Best Practice Recommendations Rehabilitation, Recovery, and Community Participation Following Stroke, Part Two: Delivery of Stroke Rehabilitation to Optimize Functional Recovery, 7th Edition Update 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Canadian Stroke Best Practice Recommendations Rehabilitation, Recovery, and Community Participation Following Stroke, Part Three: Optimizing Activity and Community Participation Following Stroke , 7th Edition Update, 2025.

American journal of physical medicine & rehabilitation·2025

Related Experiment Video

Updated: Feb 15, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K

Emicizumab-kxwh: First Global Approval.

Lesley J Scott1, Esther S Kim2

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|January 23, 2018
PubMed
Summary

Emicizumab-kxwh (Hemlibra) offers a new prophylactic treatment for hemophilia A patients with inhibitors. This bispecific antibody restores effective hemostasis, reducing bleeding episodes in adults and children.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Hemophilia A is a genetic bleeding disorder caused by deficiency in coagulation factor VIII (FVIII).
  • Patients with FVIII inhibitors present a significant challenge in hemophilia A management.
  • Current treatments may be less effective or associated with complications in this patient population.

Purpose of the Study:

  • To summarize the development milestones of emicizumab-kxwh.
  • To highlight the approval of emicizumab-kxwh for routine prophylaxis in hemophilia A patients with FVIII inhibitors.
  • To discuss the potential of emicizumab-kxwh in managing hemophilia A.

Main Methods:

  • Review of preclinical and clinical development data for emicizumab-kxwh.
  • Analysis of regulatory submissions and approvals.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.7K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Related Experiment Videos

Last Updated: Feb 15, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.7K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K
  • Summary of the mechanism of action of emicizumab-kxwh.

    • Main Results:

    • Emicizumab-kxwh is a bispecific monoclonal antibody that bridges activated FIX and FX.
    • Subcutaneous emicizumab-kxwh is approved in the USA for routine prophylaxis in hemophilia A patients with FVIII inhibitors.
    • Phase 3 development is ongoing for hemophilia A without FVIII inhibitors.

    Conclusions:

    • Emicizumab-kxwh represents a significant advancement in hemophilia A treatment.
    • The drug offers a novel prophylactic option for patients with FVIII inhibitors.
    • Further development is exploring its use in a broader hemophilia A population.